Scribd Logo
Upload

Welcome to Scribd!

  • 26 views

    Cipla Altman's Z Score

    Uploaded by

    yash telang

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Cipla Altman's Z Score

    Uploaded by

    yash telang
    26 views2 pages

    Original Title

    Cipla Altman's Z score

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    26 views2 pages

    Cipla Altman's Z Score

    Uploaded by

    yash telang

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 2

    CIPLA LTD

    (CIPLA | BSE Code: 500087)


    INR 1485.25
    52 Week (High - INR 4609 & Low - 3292)

    Altman's Z Score Analysis


    Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses
    on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other
    medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest
    drug producer in India.

    Financial Summary
    Working cpaital/ Total asset Retained Earnings / Total Assets EBIT / Total Assets

    2017 2018 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023

    Sales / Total Assets Market Cap / Long term Liabilities

    2017 2018 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023

    Recent Updates
    • Cipla shares jump 7% after Q3 earnings, hit new record high.
    • The company on Monday reported a 32.7% YoY jump in its consolidated net profit at ₹1,056 crore.
    • Revenue from Indian business surged by 12% in Q3, while US business reported the highest ever quarterly revenue of $230 million
    at 18%.
    • South Africa continued its growth journey by posting a solid 15% YoY increase in revenue in local currency terms.
    • The operating profit came in at ₹1,748 crore, an increase of 24.2% YoY, while the EBITDA margin expanded by over 200 basis points

    Page 1
    Altman's Z Score Analysis Calculation
    Working Capital / Total Assets
    Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Mar-23
    Working Capital 4,508.4 6,136.9 6,489.8 6,601.0 7,146.5 8,897.4 10,294.7
    Total Assets 20,868.9 22,672.9 23,761.9 23,422.8 24,855.3 26,857.2 29,300.0
    Working Capital / Total Assets (A) 21.60% 27.07% 27.31% 28.18% 28.75% 33.13% 35.14%

    Retained Earnings / Total Assets


    Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Mar-23
    Retained Earnings 881.5 1,177.8 1,267.9 1,224.5 1,998.1 2,156.1 2,149.4
    Total Assets 20,868.9 22,672.9 23,761.9 23,422.8 24,855.3 26,857.2 29,300.0
    Retained Earnings / Total Assets (B) 4.22% 5.19% 5.34% 5.23% 8.04% 8.03% 7.34%

    EBIT / Total Assets


    EBIT 1,173.4 1,503.6 1,771.0 2,031.3 3,184.8 3,500.8 3,854.9
    Total Assets 20,868.9 22,672.9 23,761.9 23,422.8 24,855.3 26,857.2 29,300.0
    EBIT/Total Assets (C) 5.62% 6.63% 7.45% 8.67% 12.81% 13.03% 13.16%

    Market Cap / Long term Liabilities


    Market Cap 47,703.4 43,915.2 42,613.5 34,091.7 65,734.8 82,137.7 72,683.9
    Long term Liabilities 4,112.7 4,098.1 4,316.2 2,816.4 2,014.4 1,055.8 803.1
    Market Cap / Long term Liabilities (D) 1159.92% 1071.61% 987.29% 1210.46% 3263.23% 7779.81% 9050.19%

    Sales / Total Assets


    Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Mar-23
    Total Sales 14,394.3 15,155.7 16,362.4 17,132.0 19,159.6 21,763.3 22,753.1
    Total Assets 20,868.9 22,672.9 23,761.9 23,422.8 24,855.3 26,857.2 29,300.0
    Return on Asset (E) 68.97% 66.85% 68.86% 73.14% 77.08% 81.03% 77.66%

    Altman's Z Score
    Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Mar-23
    Final Score 5.3 4.9 4.7 6.0 16.0 38.8 43.1
    Financial Stability Strong Strong Strong Strong Strong Strong Strong
    Disclaimer : This report is made as part of educational assignment and is meant for educational purpose only. The author of the report is not liable for any losses due to actions taken
    basis this report. It is advisable to consult SEBI registered reasearch analyst before making any investments

    Page 2

    You might also like